MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Accuray Incorporated Total Assets 2011-2025 | ARAY
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Accuray Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 470 M | 469 M | 479 M | 473 M | 480 M | 491 M | 438 M | 379 M | 406 M | 469 M | 470 M | 495 M | 476 M | 473 M | 456 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 495 M | 379 M | 462 M |
Quarterly Total Assets Accuray Incorporated
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 457 M | 470 M | 484 M | 478 M | 473 M | 469 M | 463 M | 476 M | 477 M | 479 M | 476 M | 469 M | 466 M | 473 M | 469 M | 476 M | 476 M | 480 M | 480 M | 478 M | 465 M | 491 M | 491 M | 479 M | 464 M | 438 M | 438 M | 386 M | 369 M | 379 M | 379 M | 414 M | 394 M | 406 M | 406 M | 415 M | 423 M | 469 M | 469 M | 473 M | 462 M | 467 M | 470 M | 468 M | 460 M | 495 M | 495 M | 485 M | 473 M | 476 M | 476 M | 416 M | 438 M | 473 M | 473 M | 492 M | 500 M | 456 M | 456 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 500 M | 369 M | 458 M |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B |  USA |
 |
Abiomed
ABMD
|
1.49 B | - | - | $ 17.2 B | USA |
 |
Acutus Medical
AFIB
|
54 M | - | -26.83 % | $ 2.62 M | USA |
 |
Apyx Medical Corporation
APYX
|
79.2 M | $ 3.82 | -1.04 % | $ 132 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | USA |
 |
Bio-Rad Laboratories
BIO
|
9.36 B | $ 307.08 | -0.33 % | $ 8.66 B | USA |
 |
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M | USA |
 |
BioSig Technologies
BSGM
|
842 K | - | 37.08 % | $ 85.7 M | USA |
 |
Bruker Corporation
BRKR
|
5.81 B | $ 45.69 | 1.24 % | $ 6.81 K | USA |
 |
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | USA |
 |
Abbott Laboratories
ABT
|
81.4 B | $ 128.67 | 2.55 % | $ 224 B | USA |
 |
Boston Scientific Corporation
BSX
|
39.4 B | $ 91.95 | -0.67 % | $ 135 B | USA |
 |
Conformis
CFMS
|
94 M | - | - | $ 16.4 M | USA |
 |
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | USA |
 |
EDAP TMS S.A.
EDAP
|
86.1 M | $ 3.18 | 10.56 % | $ 119 M |  France |
 |
Cardiovascular Systems
CSII
|
323 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
346 M | - | -10.19 % | $ 1.99 M | USA |
 |
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
66.2 M | - | - | $ 111 M |  Canada |
 |
Eargo
EAR
|
132 M | - | - | $ 10.2 M | USA |
 |
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | USA |
 |
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
498 M | $ 9.58 | -2.84 % | $ 688 M | Israel |
 |
InMode Ltd.
INMD
|
786 M | $ 14.35 | -1.1 % | $ 1.14 B | Israel |
 |
IRIDEX Corporation
IRIX
|
34.4 M | $ 0.99 | 7.52 % | $ 16 M | USA |
 |
IRadimed Corporation
IRMD
|
98.3 M | $ 96.99 | 0.79 % | $ 1.23 B | USA |
 |
Second Sight Medical Products
EYES
|
41.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
Align Technology
ALGN
|
6.21 B | $ 163.04 | -1.44 % | $ 12.2 B | USA |
 |
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
39.2 M | $ 12.5 | -1.66 % | $ 338 M | USA |
 |
FONAR Corporation
FONR
|
199 M | $ 14.9 | 0.99 % | $ 97.7 M | USA |
 |
AxoGen
AXGN
|
204 M | $ 30.0 | -1.3 % | $ 1.33 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
659 M | - | - | $ 3.31 B | USA |
 |
GBS
GBS
|
8.25 M | - | -0.57 % | $ 7.12 M | USA |
 |
CONMED Corporation
CNMD
|
2.31 B | $ 40.3 | -1.29 % | $ 1.24 B | USA |
 |
LivaNova PLC
LIVN
|
2.51 B | $ 63.28 | 0.84 % | $ 3.43 B |  Britain |
 |
OrthoPediatrics Corp.
KIDS
|
473 M | $ 17.83 | 1.31 % | $ 411 M | USA |
 |
Globus Medical
GMED
|
5.25 B | $ 86.73 | 0.05 % | $ 11.8 B | USA |
|
LENSAR
LNSR
|
66.3 M | $ 11.51 | -0.04 % | $ 133 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
4.04 B | $ 13.51 | 0.67 % | $ 1.04 B | USA |
 |
Aziyo Biologics
AZYO
|
43.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
Alphatec Holdings
ATEC
|
776 M | $ 19.79 | -0.85 % | $ 2.83 B | USA |
 |
Aethlon Medical
AEMD
|
7.36 M | $ 3.07 | -9.71 % | $ 4.79 M | USA |
 |
Establishment Labs Holdings
ESTA
|
347 M | $ 72.39 | -0.17 % | $ 2.04 B |  Costa-rica |